Drug intelligence / Profile preview

anti-CD47 F(ab')2

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

anti-CD47 F(ab')2 is a monoclonal antibody fragment consisting of two antigen-binding (Fab) regions linked by a disulfide bond, lacking the crystallizable fragment (Fc) region. It specifically targets CD47 (Cluster of Differentiation 47), a cell-surface protein often overexpressed on cancer cells that functions as a "don't eat me" signal by interacting with SIRPα on macrophages. By blocking this interaction, the F(ab')2 fragment neutralizes the inhibitory signal, thereby promoting the phagocytosis of malignant cells by the innate immune system. The use of a F(ab')2 fragment instead of a full IgG molecule allows for the blockade of the CD47-SIRPα axis without inducing Fc-mediated effector functions or certain toxicities, such as hemagglutination, which are sometimes associated with full-length anti-CD47 antibodies. In research settings, it is frequently investigated in combination with other tumor-targeting antibodies to synergistically enhance antibody-dependent cellular phagocytosis (ADCP).

Other names
anti-CD47 F(ab')2 antibodyCD47-blocking F(ab')2
02

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on anti-CD47 F(ab')2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD47 F(ab')2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call